-risk patients
undergoing TCAR with the ENROUTE neuroprotection
and stent system showed the lowest stroke risk (1.4%)
compared with all other prospective and randomized

clinical trials of endovascular carotid intervention.177
These ﬁndings persisted up to 1 year with a 0.6% incidence of ipsilateral stroke and 3.7% overall mortality after
TCAR with dynamic ﬂow reversal.178